Multiple Myeloma Clinical Trials in Barcelona

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Recruiting
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Beverly Hills, California
  • +85 more
2021-10-14
Oct 14, 2021
J
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
Active, not recruiting
  • Multiple Myeloma
  • No intervention
  • Tucson, Arizona
  • +85 more
2021-10-14
Oct 14, 2021
J
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Active, not recruiting
  • Multiple Myeloma
  • Whittier, California
  • +113 more
2021-10-14
Oct 14, 2021
J
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Dara SC
  • Dara IV
  • Boston, Massachusetts
  • +146 more
2021-10-14
Oct 14, 2021
J
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +123 more
2021-10-14
Oct 14, 2021
J
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +100 more
2021-10-14
Oct 14, 2021
A
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Scottsdale, Arizona
  • +200 more
2021-10-11
Oct 11, 2021
J
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Duarte, California
  • +24 more
2021-10-07
Oct 7, 2021
J
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Recruiting
  • Multiple Myeloma
  • Carfilzomib 20 mg/m^2
  • +4 more
  • Gilbert, Arizona
  • +112 more
2021-10-07
Oct 7, 2021
J
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Active, not recruiting
  • Multiple Myeloma
  • Southington, Connecticut
  • +63 more
2021-10-07
Oct 7, 2021
J
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
2021-10-07
Oct 7, 2021
C
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +25 more
2021-10-05
Oct 5, 2021
A
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab (TJ011133) With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Lemzoparlimab
  • +4 more
  • Tucson, Arizona
  • +48 more
2021-10-04
Oct 4, 2021
J
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • California City, California
  • +164 more
2021-09-16
Sep 16, 2021
J
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +145 more
2021-09-16
Sep 16, 2021
G
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Pom/dex (Pomalidomide plus low dose Dexamethasone)
  • Tucson, Arizona
  • +135 more
2021-10-01
Oct 1, 2021
G
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Belantamab mafodotin frozen liquid
  • Belantamab mafodotin lyophilized powder
  • New Haven, Connecticut
  • +58 more
2021-09-30
Sep 30, 2021
C
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • +5 more
  • Duarte, California
  • +37 more
2021-09-27
Sep 27, 2021
O
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Active, not recruiting
  • Multiple Myeloma
  • Tucson, Arizona
  • +108 more
2021-09-27
Sep 27, 2021
K
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Plantation, Florida
  • +156 more
2021-09-24
Sep 24, 2021
C
Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma - 2021
Terminated
  • Multiple Myeloma
    • Zaragoza, Aragón, Spain
    • +43 more
    2021-09-07
    Sep 7, 2021
    H
    A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
    Recruiting
    • Multiple Myeloma in Relapse
    • +3 more
    • Gilbert, Arizona
    • +16 more
    2021-09-02
    Sep 2, 2021
    P
    Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients - 2020
    Completed
    • Multiple Myeloma
    • Filanesib, pomalidomide and dexamethasone
    • Badalona, Spain
    • +9 more
    2021-09-02
    Sep 2, 2021
    O
    A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
    Active, not recruiting
    • Multiple Myeloma
    • Whittier, California
    • +19 more
    2021-08-27
    Aug 27, 2021
    E
    A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
    Not yet recruiting
    • Multiple Myeloma
    • Lille, France
    • +41 more
    2021-08-25
    Aug 25, 2021